ADDRESSING AN UNMET MEDICAL NEED
There are very limited effective chemotherapeutic treatments for intermediate and high-risk non-muscle invasive bladder cancer. The urothelial tissue layer of the bladder, where the tumour resides, prevents the absorption of locally instilled (intravesical) chemotherapeutic agents thereby limiting their effectiveness. Sitka’s nanoparticulate drug delivery technology addresses the absorption challenges of current intravesical treatments.
IMPROVEMENT OVER CURRENT THERAPIES
Sitka’s technology combines a nanoparticulate drug delivery technology based on hyperbranched polyglycerols (HPG), with docetaxel, a well-characterized chemotherapeutic, in a single proprietary formulation designed for intravesical instillation into the bladder. In an animal model of bladder cancer, Sitka’s proprietary formulation significantly improved bladder tissue uptake and dramatically outperformed the commercially available docetaxel formulation.
Sitka’s founding scientists include Dr. Helen Burt, Associate Vice President of Research at UBC with a history of commercially successful drug-delivery technology development, Dr. Don Brooks, Professor of Pathology at UBC whose group developed the drug binding HPG polymers and Dr. Martin Gleave, a world-leading urologist at the Vancouver Prostate Centre/UBC. Together, they worked with development experts at The Centre for Drug Research and Development and CDRD Ventures Inc.